The pharmaceutical equipment industry ushered in a new round of growth, and the high-end market has become a new growth point for performance

With the increasing aging of the population, the upgrading of consumption levels, and the continuous advancement of new medical insurance policies, the demand for China's pharmaceutical industry is expanding year by year
.
According to statistics, the Chinese pharmaceutical market is expected to grow to US$145 billion by 2022
.
In this regard, analysts believe that under the accelerated development mode of China’s pharmaceutical industry, the demand for pharmaceutical equipment will be further released, and this will inject new growth momentum into the development of the pharmaceutical equipment industry, making the industry expected to explode in the short term.
Transform into steady growth
.
Pharmaceutical equipment (picture source: Pharmaceutical Network) In fact, from the booming production and sales of a large number of pharmaceutical equipment companies in the first half of this year, their performance continues to grow, and their production and operation are stable and improving, it can be seen that as an upstream industry in the pharmaceutical industry, as well as an important sub-industry One of the pharmaceutical equipment industry has ushered in a new round of growth
.
For example, Tofflon issued a third-quarter results announcement on October 27, stating that the net profit attributable to shareholders of listed companies in the first three quarters was about 558 million yuan, a year-on-year increase of nearly double, an increase of 93.
69%
.
In addition, the third quarter report of Chutian Technology also showed that the net profit attributable to shareholders of listed companies was 401 million yuan in the first three quarters, an increase of 723.
53% year-on-year, and the net profit reached twice the net profit for the whole year of 2020
.
The industry believes that judging from the sufficient orders on hand by leading pharmaceutical companies such as Chutian Technology and Tofflon, the fourth quarter and subsequent quarters are expected to maintain high growth
.
It should be noted that the continuous growth of the market also means that the industry concentration will continue to increase in the future, and market competition will become more intense
.
For pharmaceutical equipment companies, in order to grab more markets, they need to grasp the current situation and future development trends of the industry, create new competitive advantages and make arrangements in advance
.
The author has learned that many pharmaceutical equipment companies have their own layout priorities
.
Among them, from an overall point of view, increasing the R&D and upgrading of high-end equipment has obviously become the main choice for related companies
.
For example, Chutian Technology is one of my country's major companies entering the high-end pharmaceutical equipment market
.
At present, it has formed stainless steel reaction fermentation system, chromatographic separation and purification system, liquid preparation system and other related products in the field of biological front-end
.
However, according to its semi-annual report, Chutian Technology has been able to provide a variety of highly intelligent, cost-effective biopharmaceutical equipment, and continues to increase its investment in bioengineering product lines
.
It clearly stated that in the future, it will continue to implement the development strategy of "one vertical, one horizontal and one platform", leverage the synergy effects of various subsidiaries, increase investment in research and development and advanced manufacturing technology, and actively seize market opportunities in AI and intelligent equipment, and Steadily promote the construction of production capacity, and strive to achieve the strategic goal of reaching 20 billion yuan in sales in 2030
.
In addition to Chutian Technology, many companies have made many breakthroughs in high-end equipment through continuous R&D investment
.
Earlier, Canaan Technology stated that the company had a breakthrough iteration in wet granulation technology
.
It uses a specially developed and designed new granulation structure to achieve a primary yield rate of more than 97% for 10-80 mesh particles and a particle size ratio of more than 92% for 10-40 mesh.
The production capacity can reach 700 kg/h, and the particle size distribution obtained is more Focus
.
According to its experimental results, the new wet granulation iterative technology can specifically solve the technical problems of pediatric chemical drug granules or dry suspension products, meet customers' alternatives to swing granulation, improve the primary yield, production efficiency, and granulation linkage line The requirements of closed production have provided new technological solutions for the wet granulation process
.
In general, judging from the fact that many pharmaceutical equipment companies are striving to build higher-end pharmaceutical equipment, and the annual R&D investment is showing an increasing trend year by year, the high-end market has become a new force for pharmaceutical equipment companies
.
The industry predicts that with the pharmaceutical equipment industry ushering in a new round of growth, the high-end market will provide more assistance to the performance growth of pharmaceutical equipment companies
.
In this context, relevant companies should seize development opportunities, continue to tackle key problems, break the "stuck neck" bottleneck, accelerate the pace of domestic substitution, further enhance their own market competitiveness, expand market share, and help China's pharmaceutical industry better To develop towards high quality
.